Welcome to our dedicated page for Acumen Pharmaceuticals SEC filings (Ticker: ABOS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Acumen files periodic reports and current reports with the U.S. Securities and Exchange Commission, including Forms 10‑K, 10‑Q and 8‑K, in connection with its development of sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of early Alzheimer’s disease.
Through its 8‑K filings, Acumen reports material events such as quarterly financial results, business highlights, strategic collaboration agreements and changes in its Board of Directors. For example, recent 8‑Ks have covered the company’s financial condition, the posting of updated corporate presentations, and the appointment of a new chairman of the board. These filings complement press releases that discuss the progress of the Phase 2 ALTITUDE-AD trial, the Enhanced Brain Delivery (EBD™) collaboration with JCR Pharmaceuticals, and other corporate developments.
On this page, users can also track how Acumen describes its status as an emerging growth company, its listing of common stock on The Nasdaq Global Select Market under the symbol ABOS, and its use of collaborations and option agreements to support development of AβO-targeted therapies. While detailed insider trading information would appear in Form 4 filings and executive compensation in proxy materials, this hub focuses on the full range of EDGAR-reported documents.
Stock Titan enhances these filings with AI-powered summaries that explain key points, highlight important sections in lengthy reports such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q, and help readers quickly understand how new disclosures relate to Acumen’s Alzheimer’s disease programs and financial position.
Acumen Pharmaceuticals, Inc. reported a planned sale of its common stock under Rule 144. A holder intends to sell 1,097 shares of common stock through Merrill Lynch on the NASDAQ, with an aggregate market value of $2,176.24 and 60,573,425 shares of common stock outstanding.
The shares to be sold were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted as part of the issuer’s equity compensation plan, with the same date listed for payment of the award.
A person associated with Acumen Pharmaceuticals, Inc. has filed a notice to sell 1,700 shares of common stock under Rule 144. The planned sale is through Merrill Lynch on the NASDAQ, with an approximate sale date of 01/07/2026 and an aggregate market value of $3,379.50 based on the price used in the notice.
The 1,700 shares arose from the vesting of a restricted stock unit award on 01/06/2026, granted as part of the issuer’s equity compensation plan. The notice also states that the issuer has 60,573,425 shares of common stock outstanding, providing context for the size of the proposed sale.
Acumen Pharmaceuticals insider Derek Meisner has filed a Form 144 notice to sell shares of the company’s common stock. The filing covers 11,770 shares to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $23,414.63 and an approximate sale date of January 7, 2026. The securities to be sold were acquired through the vesting of restricted stock unit awards granted as part of the issuer’s equity compensation plan on multiple dates in 2025 and 2026.
Over the prior three months, the filing reports that Derek Meisner sold 4,000 shares of Acumen Pharmaceuticals common stock on January 5, 2026 for gross proceeds of $7,838.00, and 10,898 shares on January 6, 2026 for gross proceeds of $21,437.56.
Acumen Pharmaceuticals insider plans a small stock sale under Rule 144. The filing reports an intended sale of 1,700 shares of common stock through Merrill Lynch on or around 01/07/2026 on NASDAQ. The shares were acquired on 01/06/2026 through the vesting of a restricted stock unit award granted under the company’s equity compensation plan.
The notice also lists recent activity: the same seller disposed of 4,000 common shares on 01/05/2026 for gross proceeds of $7,832.50, and 3,618 shares on 01/06/2026 for gross proceeds of $7,114.46. The filing indicates there are 60,573,425 common shares outstanding. The person on whose behalf the shares are being sold represents that they are not aware of undisclosed material adverse information about Acumen’s operations.
Acumen Pharmaceuticals insider plans to sell 5,805 common shares under Rule 144. The shares are to be sold through Merrill Lynch, with an aggregate market value of $11,565.85, on or about January 7, 2026 on the NASDAQ exchange. The filing shows these shares relate to the vesting of restricted stock unit awards of 4,105 shares on January 2, 2026 and 1,700 shares on January 6, 2026, granted as part of the issuer’s equity compensation plan. The notice also reports that Matt Zuga sold 4,000 common shares for $7,842.33 on January 5, 2026 and 5,100 shares for $10,027.50 on January 6, 2026. Common shares outstanding are listed as 60,573,425.
Acumen Pharmaceuticals insider Daniel O'Connell has filed a Form 144 notice to sell up to 37,755 shares of common stock. The planned sale is to be executed through Merrill Lynch, with an indicated aggregate market value of $74,980.95, and the shares are listed on the NASDAQ. The underlying 37,755 shares were acquired on 01/02/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan.
The notice also lists recent activity over the past three months, including sales of 4,649 shares of common stock on 01/05/2026 for gross proceeds of $9,163.33 and 5,102 shares on 01/06/2026 for gross proceeds of $10,031.44. The filing states that the person for whose account the securities are to be sold represents they do not know of any material adverse, nonpublic information about the company’s operations.
Acumen Pharmaceuticals insider Derek Meisner has filed a notice to sell common stock. The filing covers 10,898 shares of Acumen Pharmaceuticals common stock to be sold through Merrill Lynch on NASDAQ, with an aggregate market value of $21,437.56 and an approximate sale date of 01/06/2026. Shares of common stock outstanding were 60,573,425 at the time referenced; this is a baseline figure, not the amount being sold.
The securities to be sold were acquired through the vesting of restricted stock unit awards from Acumen Pharmaceuticals, Inc., including 7,097 shares acquired on 01/02/2026 and 3,801 shares acquired on 01/02/2025 as part of the issuer’s equity compensation plan. Over the past three months, Meisner has also sold 4,000 shares of common stock for gross proceeds of $7,838.00.
Acumen Pharmaceuticals insider Daniel O’Connell filed a Form 144 notice to sell common stock of ABOS. The planned sale covers 5,102 shares of common stock through Merrill Lynch on NASDAQ, with an aggregate market value of $10,031.44 based on the figures shown. These shares were acquired on 01/02/2026 through the vesting of a restricted stock unit award granted under the issuer’s equity compensation plan, with the same date shown for payment.
The notice also discloses that during the past three months O’Connell sold 4,649 shares of Acumen Pharmaceuticals common stock on 01/05/2026 for gross proceeds of $9,163.33. By signing the notice, the seller represents that he does not know of any undisclosed material adverse information about the company’s current or prospective operations.
Acumen Pharmaceuticals filed a prospectus supplement for an amended at-the-market program to sell up to $50,000,000 of common stock through BofA Securities, Stifel and BTIG, who may receive commissions of up to 3.0% of the gross sales price per share. Sales may occur on Nasdaq or otherwise at market-related or negotiated prices.
The company expects to use any net proceeds primarily to fund ongoing and future trials of sabirnetug, chemistry and manufacturing work, and for working capital and general corporate purposes. Through the date of the supplement, Acumen has sold $12.3 million under the Sales Agreement, leaving $37.7 million available.
Shares outstanding were 60,573,425 as of September 30, 2025. The company illustrates that, assuming sales at $1.97 (the November 11, 2025 last sale price), total shares outstanding could be up to 85,954,135; the actual share count will vary with sale prices and volumes.
Acumen Pharmaceuticals filed a Form 8-K announcing it reported financial results and business highlights for the quarter ended September 30, 2025. The company furnished the details via an earnings press release attached as Exhibit 99.1.
Acumen also furnished an updated corporate presentation (Exhibit 99.2) and posted it on its investor website. The presentation was updated to reflect the company’s cash, cash equivalents and marketable securities balance as of September 30, 2025. The information in Items 2.02 and 7.01 was furnished rather than filed.